BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 38610969)

  • 1. Response to comment on: "Comparison of perioperative and histopathologic outcomes among neoadjuvant treatment strategies for locoregional gastric cancer".
    Janczewski LM; Bentrem DJ; Chawla A
    J Surg Oncol; 2024 May; ():. PubMed ID: 38798243
    [No Abstract]   [Full Text] [Related]  

  • 2. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
    Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
    Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FLOT or CROSS for gastroesophageal junction cancers-is the debate over yet?
    Shariff B; Mehta R
    Chin Clin Oncol; 2023 Jun; 12(3):24. PubMed ID: 37303220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT.
    Geerts JFM; van der Zijden CJ; van der Sluis PC; Spaander MCW; Nieuwenhuijzen GAP; Rosman C; van Laarhoven HWM; Verhoeven RHA; Wijnhoven BPL; Lagarde SM; Mostert B
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610969
    [No Abstract]   [Full Text] [Related]  

  • 5. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
    BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
    Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
    Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Trends in Volume and Surgical Outcomes in Gastric Cancer.
    Marano L; Verre L; Carbone L; Poto GE; Fusario D; Venezia DF; Calomino N; Kaźmierczak-Siedlecka K; Polom K; Marrelli D; Roviello F; Kok JHH; Vashist Y
    J Clin Med; 2023 Apr; 12(7):. PubMed ID: 37048791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: A population-based study.
    Kuijper SC; Pape M; Vissers PAJ; Jeene PM; Kouwenhoven EA; Haj Mohammad N; Ruurda JP; Sosef MN; Verhoeven RHA; van Laarhoven HWM
    Int J Cancer; 2023 Jul; 153(1):33-43. PubMed ID: 36855965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
    Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
    Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals new therapeutic strategies.
    Li Y; Xu C; Wang B; Xu F; Ma F; Qu Y; Jiang D; Li K; Feng J; Tian S; Wu X; Wang Y; Liu Y; Qin Z; Liu Y; Qin J; Song Q; Zhang X; Sujie A; Huang J; Liu T; Shen K; Zhao JY; Hou Y; Ding C
    Nat Commun; 2022 Sep; 13(1):5723. PubMed ID: 36175412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
    Moore JL; Kumar S; Santaolalla A; Patel PH; Kapiris M; Van Hemelrijck M; Maisey N; Hill M; Lagergren J; Gossage JA; Kelly M; Chaudry A; Allum WH; Baker CR; Cunningham D; Davies AR;
    Eur J Cancer; 2022 Mar; 163():180-188. PubMed ID: 35085931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer: A Multicenter Prospective Dutch Cohort Study (PLASTIC).
    Gertsen EC; Brenkman HJF; van Hillegersberg R; van Sandick JW; van Berge Henegouwen MI; Gisbertz SS; Luyer MDP; Nieuwenhuijzen GAP; van Lanschot JJB; Lagarde SM; Wijnhoven BPL; de Steur WO; Hartgrink HH; Stoot JHMB; Hulsewe KWE; Spillenaar Bilgen EJ; van Det MJ; Kouwenhoven EA; van der Peet DL; Daams F; van Grieken NCT; Heisterkamp J; van Etten B; van den Berg JW; Pierie JP; Eker HH; Thijssen AY; Belt EJT; van Duijvendijk P; Wassenaar E; van Laarhoven HWM; Wevers KP; Hol L; Wessels FJ; Haj Mohammad N; van der Meulen MP; Frederix GWJ; Vegt E; Siersema PD; Ruurda JP;
    JAMA Surg; 2021 Dec; 156(12):e215340. PubMed ID: 34705049
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.